info@p-95.com

Clinical Trial Delivery

Comprehensive Clinical Trial Support for Vaccines and Infectious Disease.

Data, Analysis and writing

Our data management, biostatistics, safety management and medical writing teams ensure data integrity and insightful analysis for vaccines and drugs across all stages of development.

Epidemiology and Real-World Evidence (RWE) Solutions

Comprehensive Epidemiology and RWE solutions for Vaccines and Infectious Diseases.

Africa and LMICs

Expanding Clinical and Epidemiological Horizons: Expertise in Africa, LMICs, and Beyond.

VIEW ALL SERVICES

Lyme Publications

P95 has collaborated in a large review study about Lyme disease. This study has involved databases/surveillance and systematic reviews focusing on Lyme disease incidence, epidemiology, hospitalization, and clinical manifestations, among other outcomes, in different regions of the World. Launched in 2020, the study involved many P95 employees and has now resulted in nine publications in a special issue of the Vector-Borne and Zoonotic Diseases Journal:

➡  Burn L, Vyse A, Pilz A, Tran TMP, Fletcher MA, Angulo FJ, Gessner BD, Moïsi JC, Stark JH. Incidence of Lyme Borreliosis in Europe: A Systematic Review (2005-2020). Vector Borne Zoonotic Dis. 2023 Apr;23(4):172-194. doi: 10.1089/vbz.2022.0070. PMID: 37071407; PMCID: PMC10122234.

➡ Nuttens C, Bessou A, Duret S, Skufca J, Blanc E, Pilz A, Gessner BD, Faucher JF, Stark JH. Epidemiology of Lyme Borreliosis in France in Primary Care and Hospital Settings, 2010-2019. Vector Borne Zoonotic Dis. 2023 Apr;23(4):221-229. doi: 10.1089/vbz.2022.0050. PMID: 37071406; PMCID: PMC10122229.

➡  Burn L, Tran TMP, Pilz A, Vyse A, Fletcher MA, Angulo FJ, Gessner BD, Moïsi JC, Jodar L, Stark JH. Incidence of Lyme Borreliosis in Europe from National Surveillance Systems (2005-2020). Vector Borne Zoonotic Dis. 2023 Apr;23(4):156-171. doi: 10.1089/vbz.2022.0071. PMID: 37071405; PMCID: PMC10122223.

➡ Paradowska-Stankiewicz I, Zbrzeźniak J, Skufca J, Nagarajan A, Ochocka P, Pilz A, Vyse A, Begier E, Dzingina M, Blum M, Riera-Montes M, Gessner BD, Stark JH. A Retrospective Database Study of Lyme Borreliosis Incidence in Poland from 2015 to 2019: A Public Health Concern. Vector Borne Zoonotic Dis. 2023 Apr;23(4):247-255. doi: 10.1089/vbz.2022.0049. Epub 2023 Jan 27. PMID: 37071404; PMCID: PMC10122228

➡  Houben E, de Jong H, Penning-van Beest F, Kuiper J, Holthuis E, Blum M, Skufca J, Riera-Montes M, Gessner BD, Pilz A, Vyse AJ, Begier E, Dzingina M, Herings R, Stark JH. Incidence of Lyme Borreliosis in the Dutch General Practice Population: A Large-Scale Population-Based Cohort Study Across the Netherlands Between 2015 and 2019. Vector Borne Zoonotic Dis. 2023 Apr;23(4):230-236. doi: 10.1089/vbz.2022.0048. Epub 2023 Jan 27. PMID: 37071403; PMCID: PMC10122225.

➡  Burn L, Pilz A, Vyse A, Gutiérrez Rabá AV, Angulo FJ, Tran TMP, Fletcher MA, Gessner BD, Moïsi JC, Stark JH. Seroprevalence of Lyme Borreliosis in Europe: Results from a Systematic Literature Review (2005-2020). Vector Borne Zoonotic Dis. 2023 Apr;23(4):195-220. doi: 10.1089/vbz.2022.0069. PMID: 37071401; PMCID: PMC10122246.

➡  Skufca J, De Smedt N, Pilz A, Vyse A, Begier E, Blum M, Riera M, Gessner BD, Stark JH. Incidence of Lyme Borreliosis in Finland: Exploring Observed Trends Over Time Using Public Surveillance Data, 2015-2020. Vector Borne Zoonotic Dis. 2023 Apr;23(4):256-264. doi: 10.1089/vbz.2022.0047. Epub 2023 Jan 27. PMID: 37071400; PMCID: PMC10122252.

➡ Skufca J, Tran TMP, Brestrich G, Pilz A, Vyse A, Malerczyk C, Dzingina M, Begier E, Blum M, Riera-Montes M, Gessner BD, Stark JH. Incidence of Lyme Borreliosis in Germany: Exploring Observed Trends Over Time Using Public Surveillance Data, 2016-2020. Vector Borne Zoonotic Dis. 2023 Apr;23(4):237-246. doi: 10.1089/vbz.2022.0046. PMID: 37071399; PMCID: PMC10122258.

➡  Nagarajan A, Skufca J, Vyse A, Pilz A, Begier E, Riera-Montes M, Gessner BD, Stark JH. The Landscape of Lyme Borreliosis Surveillance in Europe. Vector Borne Zoonotic Dis. 2023 Apr;23(4):142-155. doi: 10.1089/vbz.2022.0067. PMID: 37071402; PMCID: PMC10122255. 

P95

Pioneering Clinical Excellence in Vaccines and Infectious Diseases

Tags:

0 Comments

You May Also Like

P95’s Journey From Epidemiology Consulting to Comprehensive CRO

P95’s Journey From Epidemiology Consulting to Comprehensive CRO

In a recent interview for Ampersand Capital Partners, our CEO, Thomas Verstraeten, and Chairman, Benoit Bouche shared pivotal insights into P95’s growth from an epidemiology consulting into a global comprehensive Contract Research Organization (CRO).

Almost one year from P95’s partnership with Ampersand Capital Partners, the article dives deeper into P95’s expanding global reach, client-focused capabilities, and commitment to global health that bring our company to the forefront.